Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 11/20 | 0.44 |
| ▸ | GAA | P10253 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2143888 | 0.79 | MAPT (0.46) | MAPTGAAALDH1A1RAB9AMEN1 | |
| SCHEMBL379196 | 0.77 | MAPT (0.57) | MAPTGAAALDH1A1RAB9AMEN1 | |
| SCHEMBL3074596 | 0.75 | NOX1 (0.58) | NOX1MAPTGAAALDH1A1RAB9A | |
| SCHEMBL1005100 | 0.75 | NOX1 (0.58) | NOX1MAPTGAAALDH1A1RAB9A | |
| SCHEMBL3074599 | 0.75 | NOX1 (0.58) | NOX1MAPTGAAALDH1A1RAB9A | |
| SCHEMBL16111930 | 0.74 | NOX1 (0.62) | NOX1MAPTGAAALDH1A1RAB9A | |
| SCHEMBL16111932 | 0.74 | NOX1 (0.62) | NOX1MAPTGAAALDH1A1RAB9A | |
| SCHEMBL13109406 | 0.74 | NOX1 (0.62) | NOX1MAPTGAAALDH1A1RAB9A | |
| SCHEMBL11831353 | 0.73 | NOX1 (0.56) | NOX1MAPTGAAALDH1A1RAB9A | |
| SCHEMBL11831344 | 0.73 | NOX1 (0.56) | NOX1MAPTGAAALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210161937-A1 | ACTIVATION OF MITOCHONDRIAL UNCOUPLING AS A THERAPEUTIC INTERVENTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2021-06-03 | — | — | US | claimed |
| WO-2019147626-A1 | ACTIVATION OF MITOCHONDRIAL UNCOUPLING AS A THERAPEUTIC INTERVENTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-08-01 | — | — | WO | claimed |
| US-20260081034-A1 | SYSTEMS AND METHODS FOR MEASURING, LEARNING, AND USING EMERGENT PROPERTIES OF COMPLEX ADAPTIVE SYSTEMS | EMERJA CORP (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260081035-A1 | SYSTEMS AND METHODS FOR MEASURING, LEARNING, AND USING EMERGENT PROPERTIES OF COMPLEX ADAPTIVE SYSTEMS | EMERJA CORP (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250382328-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | JENIUS PHARMA LLC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12454549-B2 | Treatments for diseases and disorders that involve oxidative stress | JENIUS PHARMA, LLC (US) | 2025-10-28 | — | — | US | disclosed |
| US-12312599-B2 | Methods, compositions, and kits for producing beige adipocytes and treating metabolic disorders | MaineHealth (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4536265-A2 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Jenius Pharma, LLC (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20240132542-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Allegro Pharmaceuticals, LLC | 2024-04-25 | — | — | US | disclosed |
| WO-2023239716-A2 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Allegro Pharmaceuticals, LLC (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230335287-A1 | SYSTEMS AND METHODS FOR MEASURING, LEARNING, AND USING EMERGENT PROPERTIES OF COMPLEX ADAPTIVE SYSTEMS | EMERJA CORPORATION | 2023-10-19 | — | — | US | disclosed |
| EP-0511273-A4 | LIPOSOMES AS CONTRAST AGENTS FOR ULTRASONIC IMAGING | — | 1993-03-31 | — | — | EP | disclosed |
| EP-0511273-A1 | LIPOSOMES AS CONTRAST AGENTS FOR ULTRASONIC IMAGING | IMARX PHARMACEUTICAL CORP. (US) | 1992-11-04 | — | — | EP | disclosed |
| US-5149319-A | Methods for providing localized therapeutic heat to biological tissues and fluids | CEREVAST THERAPEUTICS, INC. | 1992-09-22 | — | — | US | disclosed |
| US-5123414-A | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same | CITIZENS BANK, N.A. | 1992-06-23 | — | — | US | disclosed |
| US-5088499-A | Medical diagnosis | CITIZENS BANK, N.A. | 1992-02-18 | — | — | US | disclosed |
| WO-1991009629-A1 | LIPOSOMES AS CONTRAST AGENTS FOR ULTRASONIC IMAGING | UNGER EVAN C (US) | 1991-07-11 | — | — | WO | disclosed |
| EP-0412211-A1 | Cancer therapy system | THERAPEUTICAL SYSTEMS CORPORATION (US) | 1991-02-13 | — | — | EP | disclosed |
| US-4935450-A | Cancer therapy system for effecting oncolysis of malignant neoplasms | THERAPEUTICAL SYSTEMS CORPORATION (US) | 1990-06-19 | — | — | US | disclosed |
| US-4724234-A | ADMINISTERING NUTRITIONAL REGIMEN AND AGENTS WHICH UNCOUPLE OXIDATIVE PHOSPHORYLATION | THERAPEUTICAL SYSTEMS CORP. (US) | 1988-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132542-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | GPX4, GPX1, TXNRD2 | NOX1 50/4885MAPT 694/4885GAA 174/4885 |
| US-12454549-B2 | Treatments for diseases and disorders that involve oxidative stress | GPX4, GPX1, TXNRD2 | NOX1 50/4885MAPT 694/4885GAA 174/4885 |
| US-20250382328-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | GPX4, GPX1, TXNRD2 | NOX1 50/4885MAPT 694/4885GAA 174/4885 |
| US-20260081035-A1 | SYSTEMS AND METHODS FOR MEASURING, LEARNING, AND USING EMERGENT PROPERTIES OF COMPLEX ADAPTIVE SYSTEMS | PYGB, CRH, CRY1 | NOX1 4808/4885MAPT 968/4885GAA 2005/4885 |
| US-12312599-B2 | Methods, compositions, and kits for producing beige adipocytes and treating metabolic disorders | FABP4, LIPC, PNLIP | NOX1 2907/4885MAPT 3885/4885GAA 269/4885 |
| US-20260081034-A1 | SYSTEMS AND METHODS FOR MEASURING, LEARNING, AND USING EMERGENT PROPERTIES OF COMPLEX ADAPTIVE SYSTEMS | CRH, HCRTR1, PER2 | NOX1 4763/4885MAPT 1473/4885GAA 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.